Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer

Official title

SURVIVE (Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer) - a Partially Double-blinded, Multi-center, Randomized, Controlled Superiority Study

Overview

The goal of this clinical study is to evaluate the potential benefits of intensified surveillance versus standard surveillance in medium-risk and high-risk early breast cancer patients. The main questions it aims to answer are: * Comparison of the 5-year ob´verall survival rates between patients in the Standard Surveillance arm versus patients in the liquid-biopsy guided Intensive Surveillance arm * Determination of the Overall Lead Time Effect generated due to tumor marker/CTC/ctDNA guided Intensive Surveillance compared to Standard Surveillance after primary therapy in early breast cancer patients. Participants will recieve regular blood drawals. Solely the blood samples of the intensive surveillance arm will be analysed for prospective tumor markers/CTCs/ctDNAs. Abnormal findings of either marker will trigger diagnostic imaging to search for possible metastases. The blood samples of the standard surveillance arm will solely be biobanked for future research purposes.

Detailed description

This is a partially double-blinded, multi-center, randomized, controlled superiority study to evaluate the potential benefits of intensified surveillance versus standard surveillance in medium-risk and high-risk early breast cancer patients.

3500 patients will be enrolled after completion of primary anti-tumor therapy (adjuvant chemotherapy, surgery or radiotherapy, whichever occurs last) and randomized in a 1:1 ratio to receive:

* Standard Surveillance according to national guidelines or * Intensive Surveillance with additional testing of blood samples for prospective tumor markers (CA27.29, CA125, CEA), CTC and ctDNA

In both study arms patients will receive standard surveillance according to national guidelines, including clinical follow-up visits every 3 months for the first 3 years and every 6 months for the following 2 years. Additionally, blood samples will be drawn and Quality of Life (QoL) will be analyzed at these clinical follow-up visits in both arms.

In the Standard Surveillance arm blood samples will be stored in a biobank. In the Intensive Surveillance arm blood samples will be tested for prospective tumor markers (CA27.29, CA125, CEA), CTCs and ctDNA. Abnormal findings of either marker (CA27.29 or CA125 or CEA or CTC or ctDNA) will trigger diagnostic imaging. Additionally, blood samples will be stored in a biobank for retrospective analysis.

In both study arms detection of distant recurrence will terminate the surveillance protocol and treatment will be initiated according to national guidelines.

Planned enrollment period is approximately 24 months, total study duration is approximately 144 months (2-year recruitment period, 5-year interventional period, 5-year follow up period). In terms of long-term follow-up after end of study, patients have the possibility to participate in the patient self-reporting registry (Patientenselbstauskunft).

Interventions

• Diagnostic test Determination of tumormarkers (CA27.29, CEA, CA125)
  CA27.29, CEA and CA125 will be measured with the AIA®-CL1200 by TOSOH BIOSCIENCE (TOSOH CORPORATION, Tokyo, Japan). The CL AIA-PACK assays are two-step chemiluminescence enzyme immunoassay kits. CA27.29/CEA/CA125 present in a test sample is bound to the anti- CA27.29/CEA/CA125 mouse monoclonal antibody immobilized on the magnetic microparticles in one cell (Cell-I). After first incubation, the magnetic microparticles are washed and the enzyme-labeled anti- CA27.29/CEA/CA125 mouse monoclonal anti
• Diagnostic test Determination of CTC levels
  CTCs will be analyzed using the CellSearch® System (Menarini Silicon Biosystems). The CellSearch® system is designed to enumerate CTCs of epithelial origin (CD45-, EpCAM+, cytokeratin 8+ / 18+ and/or 19+). The basic principle is linking a magnetic ferrofluid reagent that contains i. a. antibodies targeting the EpCAM antigen to CTCs. After steps of immunomagnetic capture and enrichment as well as addition of fluorescent reagents (that contain anti-CK-PE, DAPI and anti-CD45-APC), the automatic dis
• Diagnostic test Determination of ctDNA levels
  Presence of ctDNA will be analyzed centrally at Inivata Inc. using the RaDaRTM assay. Therefore, primary tumor tissue and peripheral blood specimens will be shipped for centralized analysis to Inivata Inc. RaDaRTM is a tumor-informed approach, beginning with whole exome sequencing of a tumor specimen from a patient's biopsy or surgical resection. SNVs and indels identified from the exome sequencing are prioritized to build a patient specific primer panel of up to 48 tumor-specific somatic varian
• Other Biobanking of blood samples
  To ensure the possibility of retrospective studies during and after the ongoing study, a biobank will be implemented.

Primary outcome measures

• Overall Survival (OS) [Time frame: 10 years]
• Overall Lead Time Effect [Time frame: 5 years]

Secondary outcome measures (12)

• Invasive disease-free survival (IDFS) [Time frame: 10 years]
• Distant disease-free survival (DDFS) [Time frame: 10 years]
• Distant recurrence-free survival (DRFS) [Time frame: 10 years]
• Breast cancer specific survival (BCSS) [Time frame: 10 years]
• Invasive breast cancer free survival (IBCFS) [Time frame: 10 years]
• Overall Survival (OS) after 10 Years [Time frame: 10 years]
• Molecular to via Imaging verified Recurrence Lead Time in the Interventional arm [Time frame: 5 years]
• Quality of life (QoL) with questionnaires: EORTC QLQ-C30 [Time frame: 10 years]
• Quality of life (QoL) with questionnaires: PA-F12 [Time frame: 10 years]
• Liquid biopsy sensitivity (CA27.29, CEA, CA125, CTC and ctDNA) [Time frame: 5 years]
• Liquid biopsy specificity (CA27.29, CEA, CA125, CTC and ctDNA) [Time frame: 5 years]
• Liquid Biopsy False-Positive Rate (CA27.29, CEA, CA125, CTC and ctDNA) [Time frame: 5 years]

Eligibility criteria

Inclusion criteria

• Written informed consent for all study procedures according to local regulatory requirements prior to beginning specific protocol procedures.
• Unilateral or bilateral primary invasive carcinoma of the breast, confirmed histologically.
• Patients with intermediate- to high-risk early breast cancer defined as either

• an indication for (neo-)adjuvant chemotherapy (regardless whether performed or not), and/or
• Large tumor (> 50 mm), and/or
• Positive lymph nodes, and/or
• High grade (>= G3). Indication to (neo-)adjuvant chemotherapy is seen as stated in the German S3 guideline for breast cancer as well as stated in the guidelines from the AGO.
• A complete resection of the primary tumor, with resection margins free of invasive carcinoma.
• Completion of primary anti-tumor therapy (adjuvant chemotherapy, surgery or radiotherapy, whichever occurs last) at least 4 weeks but no more than 24 months previously. Enrollment of patients during any kind of adjuvant therapy except chemotherapy (e.g., but not limited to endocrine therapy, antibody therapy, CDK4/6-inhibitors, PARP inhibitors, PI3K inhibitors, antibody-drug conjugates and other novel agents) is allowed.
• Availability of primary tumor tissue from core biopsy or surgical removed tissue (FFPE Slide (≥ 6 mm³, min. 10 slides, thickness: 5 µm-10 µm, area >150 mm² and 1 H\&E stained slide, minimum 20% tumor content) or FFPE Block (≥ 6 mm³ thickness: 100 µm, area: >150 mm² and 1 H\&E stained slide, minimum 20% tumor content) or Genomic DNA extracted from FFPE slides or block (≥ 600 ng, Minimum volume: 25 µL, concentration: 20 ng/µL, buffer: 10 mM Tris pH 8, 1 mM EDTA)) at timepoint of enrollment.

• Patients with primary systemic therapy: tissue from core biopsy
• Patients receiving surgery as primary therapy: surgically removed cancer tissue.
• No current clinical evidence for distant metastases.
• Females or males ≥ 18 years and ≤ 75 years of age.
• Performance status ≤ 1, Eastern Cooperative Oncology Group (ECOG) scale.
• Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion criteria

• Patients with a history of any secondary primary malignancy are ineligible with the following exceptions:

• in situ carcinoma of the cervix or
• adequately treated basal cell carcinoma of the skin or
• ipsi- or contralateral non-invasive carcinoma of the breast (DCIS).
• Patients in pregnancy or breastfeeding. If a patient gets pregnant during the participation in the interventional phase of the study (Year 1-5), an end of intervention visit will be scheduled and the patient will enter the follow-up phase of the study. Pregnancy during the follow-up phase of the study is to be reported but does not lead to an exclusion of the study.
• History of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent.
• Renal insufficiency with GFR < 30 mL/min.
• Previous or concomitant cytotoxic or other systemic antineoplastic treatment that is not used for treating the primary breast cancer.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Quadruple blind

Primary purpose

Diagnostic

Study locations

Germany · 1 center

• University Hospital Ulm Gynecology/Obstetrics — Ulm

Identifiers

NCT: NCT05658172 · SURVIVE · 01KD2202 · DRKS00030745

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗